Most Recent
Construction PRO
Sydney developer Tiptell has won its bid to exit a combustible cladding class action against 3A Composites and Halifax to bring its own claim for $15 million.
The developer of a tower in Mascot which is said to contain combustible cladding can opt out of a class action against 3A Composites and Halifax to bring its own claim for $15 million.
A judge has signed off on a $13.5 million penalty agreed to by retailer The Good Guys for making misleading statements about store credit and StoreCash schemes to customers.
A judge has rejected all but two claims by ASIC in a suit against car finance provider Money3 and criticised how the regulator ran its case, saying it had consumed an "inordinate and disproportionate amount of the judicial and administrative resources of the court".
The peak body for community legal centres has lost its bid to declass a class action alleging survivors of institutional child sexual abuse who settled their claims under the National Redress Scheme were given negligent ‘cookie cutter’ legal advice.
Saint Gobain-owned CSR has hit back at building insulation distributor Consolidated Energy's claims it engaged in anti-competitive conduct by increasing its prices during COVID-19, saying the cost increases were due to events beyond its control.
Homegoods retailer Harvey Norman is facing a class action by customers who paid more than they bargained for after being enticed by 'interest free' ads which the Federal Court has found to be misleading.
Former PricewaterhouseCoopers CEO Thomas Seymour has been banned from registering as a tax agent for four years, after the regulator found he permitted a culture within the accounting firm of sharing confidential information.
A shareholder class action over BHP’s disclosures about a Brazilian dam that collapsed 10 years ago has settled for $110 million on the eve of trial, one of a handful of class actions to settle for over $100 million.
Regeneron and Bayer have lost their bid to block generic drug maker Sandoz from launching a biosimilar of their blockbuster eye drug Eylea.